New Drug Candidates for Kidney Disease Treatment
Author Information
Author(s): Francisco Maqueda-Zelaya, Lara Valiño-Rivas, Ana Milián, Sara Gutiérrez, José Luis Aceña, Javier Garcia-Marín, Mª Dolores Sánchez-Niño, Juan J. Vaquero, Alberto Ortiz
Primary Institution: Universidad de Alcalá
Hypothesis
Can imidazolone derivatives effectively inhibit the noncanonical NF-κB activation pathway to treat chronic kidney disease?
Conclusion
The study identified imidazolone derivatives that can inhibit the noncanonical NF-κB activation pathway, showing potential as drug candidates for chronic kidney disease.
Supporting Evidence
- Imidazolone derivatives were synthesized and tested for their binding affinity to NIK.
- Three candidates showed the best affinity and were tested in cellular assays.
- Compound 3d demonstrated dose-dependent inhibition of NFκB p100 processing.
Takeaway
Researchers created new compounds that might help treat kidney disease by stopping inflammation in the kidneys.
Methodology
The study involved synthesizing imidazolone derivatives and testing their ability to inhibit the noncanonical NF-κB pathway in kidney cells.
Limitations
Further research is needed to fully understand the off-target effects and mechanisms of action of the imidazolone derivatives.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website